SonoMind

SonoMind is a medical device company based in Paris, founded in 2024. The company specializes in developing a non-invasive neuromodulation technology that uses low-intensity ultrasound to treat drug-resistant depression and other neurological and psychiatric disorders. Their core innovation is a personalized transcranial neuromodulation system that delivers ultrasound waves through a custom acoustic lens, allowing for precise targeting of deep brain regions. The technology is designed to modulate brain activity without invasive procedures, offering a potentially rapid and side-effect-free treatment alternative. SonoMind's system provides clinicians with data on treatment effects, enabling tailored therapy adjustments for individual patients. The company is preparing to launch clinical trials to further validate its technology and finalize product development. With a focus on addressing significant unmet needs in mental health, SonoMind aims to support healthcare providers and clinicians in treating patients with drug-resistant depression.

• Employees 8
• Founded 2024